To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04826198
Title Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to Niraparib in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Niraparib (REVOCAN)
Acronym REVOCAN
Recruitment Terminated
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA

Facility Status City State Zip Country Details
CHU Jean Minjoz Besançon Besancon 25000 France Details
Hospices civils de Lyon(CHU Lyon Sud) Pierre-Bénite Lyon 69310 France Details
Institut de Cancérologie de l'Ouest - St Herblain Saint-Herblain Nantes 44805 France Details
Gustave Roussy Villejuif Val De Marne 94800 France Details
Institut Bergonié Bordeaux 33076 France Details
Centre Antoine Lacassagne Nice 06189 France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field